To study complex biological processes holistically, it is imperative to take an integrative
approach that combines multi-omics data to highlight the interrelationships of the involved …

Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …

Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is
a clinically and genetically heterogeneous disease that is further classified into …

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Purpose Treatment options are limited for patients with relapsed/refractory diffuse large B-
cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint …

B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …

B cell receptor (BCR) signalling has emerged as a therapeutic target in B cell lymphomas,
but inhibiting this pathway in diffuse large B cell lymphoma (DLBCL) has benefited only a …

Purpose Rituximab (R) plus CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisone) chemotherapy is the standard of care in previously untreated diffuse large B …

Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor
behavior and outcomes, yet the identification of poor-risk groups remains challenging. In …